Menu Search
Equities

Neuland Laboratories Ltd

NEULANDLAB:NSI

Neuland Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)12,715.10
  • Today's Change75.35 / 0.60%
  • Shares traded4.14k
  • 1 Year change+245.99%
  • Beta1.3654
Data delayed at least 15 minutes, as of Sep 20 2024 06:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for Neuland Laboratories Ltd. have a median target of 11,550.00, with a high estimate of 11,700.00 and a low estimate of 11,400.00. The median estimate represents a -8.62% decrease from the last price of 12,639.75.
High-7.4%11,700.00
Med-8.6%11,550.00
Low-9.8%11,400.00

Dividends

In 2024, Neuland Laboratories Ltd reported a dividend of 14.00 INR, which represents a 40.00% increase over last year. The 2 analysts covering the company expect dividends of 10.53 INR for the upcoming fiscal year, a decrease of 24.79%.
Div growth (TTM)40.00%
More ▼

Earnings history & estimates in INR

On Aug 01, 2024, Neuland Laboratories Ltd. reported 1st quarter 2025 earnings of 60.20 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+179.92%
Neuland Laboratories Ltd. reported annual 2024 earnings of 233.89 per share on May 10, 2024.
Average growth rate+154.14%
More ▼

Revenue history & estimates in INR

Neuland Laboratories Limited had 1st quarter 2025 revenues of 4.40bn. This bettered the 3.82bn consensus of the 2 analysts covering the company. This was 21.11% above the prior year's 1st quarter results.
Average growth rate+5.33%
Neuland Laboratories Limited had revenues for the full year 2024 of 15.59bn. This was 30.84% above the prior year's results.
Average growth rate+20.11%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.